https://www.thebodypro.com/author/hiv-i-base
HIV i-Base Img

HIV i-Base

HIV i-Base is a treatment activist group, HIV-positive led and committed to providing timely HIV treatment information both to positive people and to health care professionals.

This includes technical publications like HIV Treatment Bulletin (HTB) and ARV4IDUs (Antiretrovirals for Injecting Drug Users) and non-techical treatment guides on starting and changing treatment, side effects, hepatitis C coinfection and HIV and pregnancy.

i-Base is involved in several community networks, including the UK Community Advisory Board (UK-CAB), the European AIDS Treatment Group (EATG), the European Community Advisory Board (ECAB) and the International Treatment Preparedness Coalition (ITPC) and the AIDS Treatment Activists Coalition (ATAC).

We have also developed close working relationships with NGOs in many different countries in Western and Eastern Europe and Africa. Copyright free i-Base material has been produced in over 40 languages.

We are directly involved in research with INSIGHT network, PENTA network, MRC studies in the UK, Metabolic Oversight Committee and D:A:D studies.

Treatment guides and i-Base authored articles in HTB may be reproduced by NHS, community and not-for-profit organisations without individual written permission and reproduction is encouraged. A credit and link to the original source on the i-Base Web site is always appreciated. All i-Base material remains the copyright of HIV i-Base.

HIV i-Base receives unconditional educational grants from charitable trusts, individual donors and pharmaceutical companies. All editorial policies are strictly independent of funding sources.

HIV i-Base is a registered charity no.1081905 and company limited by guarantee no. 3962064.

How to Reach HIV i-Base

4rd Floor
57a Great Suffolk Street
London
SE1 0BB
GREAT BRITAIN

Phone: +44 (0) 20 7407 8488
Treatment phoneline: 0808 800 6013, Mon., Tues., Wed. 12-4 pm
Fax: +44 (0) 20 7407 8489
E-mail: admin@i-Base.org.uk
Web: www.i-Base.info

Latest by HIV i-Base

New Option for PrEP: TAF/FTC Is Non-Inferior to TDF/FTC -- Results of Phase 3 DISCOVER Study Img

New Option for PrEP: TAF/FTC Is Non-Inferior to TDF/FTC -- Results of Phase 3 DISCOVER Study

The results from this large study are notable, showing that a new version of PrEP is at least as affective at protecting against HIV infection as the currently approved formulation.

Viral Reservoir Can Explain Persistent Low Level Viremia With Good Adherence on ART Img
Conference Coverage

Viral Reservoir Can Explain Persistent Low Level Viremia With Good Adherence on ART

A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies Img
News

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants Img
Conference Coverage

UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants

The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review Img

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review

Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.

NHS England Doubles Places on IMPACT PrEP Study to 26,000 Img
News

NHS England Doubles Places on IMPACT PrEP Study to 26,000

Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.

FDA Approves Generic TDF/3TC for Use in the U.S. Img

FDA Approves Generic TDF/3TC for Use in the U.S.

The U.S. FDA has approved Temixys, a generic combination tablet of tenofovir disoproxil fumarate plus lamivudine.

Why U=U Does Not Cover Breastfeeding Img

Why U=U Does Not Cover Breastfeeding

"Undetectable equal untransmittable" is sometimes wrongly interpreted as covering all ways that HIV can be transmitted.

How to Evaluate PrEP and Vaccines: Urgency for Next-Generation Compounds Img
Conference Coverage

How to Evaluate PrEP and Vaccines: Urgency for Next-Generation Compounds

Several presentations at the 2018 HIV Research for Prevention conference looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.

HIV Diagnoses in UK Drop for Third Year: Among All Ages, Risk Groups, and Ethnicities and Across Most UK Regions Img

HIV Diagnoses in UK Drop for Third Year: Among All Ages, Risk Groups, and Ethnicities and Across Most UK Regions

Preliminary data released by Public Health England show that HIV diagnoses dropped by 17% in 2017 compared to 2016.